Insider Selling: Illumina (NASDAQ:ILMN) Insider Sells 615 Shares

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the company’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. The trade was a 2.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Down 3.4%

NASDAQ:ILMN traded down $6.94 during trading hours on Monday, hitting $198.16. The stock had a trading volume of 2,611,564 shares, compared to its average volume of 1,908,297. The company has a market cap of $29.98 billion, a PE ratio of 36.97, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47. The business has a 50 day simple moving average of $176.70 and a two-hundred day simple moving average of $147.25. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $207.00.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.37 EPS for the current year.

Hedge Funds Weigh In On Illumina

Hedge funds and other institutional investors have recently made changes to their positions in the business. HighPoint Advisor Group LLC grew its holdings in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares in the last quarter. Elevation Wealth Partners LLC raised its stake in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares in the last quarter. Toronto Dominion Bank boosted its position in Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares during the period. Finally, Panagora Asset Management Inc. boosted its position in Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 96 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the subject of a number of research reports. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday. Canaccord Genuity Group set a $205.00 price objective on Illumina in a research report on Monday. Finally, Guggenheim upped their price objective on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $178.88.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter revenue reached approximately $1.16 billion, up 9.4% year over year and above the $1.13 billion analyst consensus. Adjusted earnings of $1.31 per share also exceeded estimates of $1.23. The company raised its 2026 revenue outlook to $4.60 billion-$4.64 billion and forecast third-quarter revenue of $1.14 billion-$1.16 billion, citing demand for clinical sequencing. Why Illumina Is Up After Raising 2026 Revenue Outlook
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $225 from $200, implying additional upside from recent trading levels. Other target increases reported overnight include targets of $210 and $230, reinforcing bullish analyst sentiment. Piper Sandler Rating Update Illumina Price Target Raised to $225 Illumina Price Target Raised to $210 Illumina Price Target Raised to $230
• Neutral Sentiment: ILMN has more than doubled over the past year and reached a fresh 52-week high. Analysts and investors are assessing whether continued clinical-sequencing growth, NovaSeq X demand and multi-omics initiatives can support further appreciation. Illumina Hits Fresh High
• Negative Sentiment: Despite the revenue and earnings beat, quarterly net income and diluted earnings per share declined year over year. Valuation is also a concern: some analyses view ILMN as potentially overvalued after its sharp rally, while market-based multiples appear expensive even where discounted-cash-flow estimates indicate further upside. Illumina Could Be Overvalued

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.